Vertex Pharma drops
5h
Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...
MoneyWeek on MSN2d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...
Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
The stock's fall snapped a four-day winning streak.
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback